THURSDAY, April 7, 2022 (HealthDay News) — The introduction of HAART (extremely energetic anti-retroviral remedy) within the mid-Nineties revolutionized the therapy of HIV/AIDS, halting illness development and dramatically extending lives.

Now, a small new examine suggests one other potential use for one of many customary HAART medicines: It halted illness development in a few quarter of sufferers who have been battling superior colon most cancers.

“What is most shocking is that this can be a class of medicine we’ve used successfully for viruses for a few years,” stated examine creator Dr. David Ting. “And now this examine opens the chance to develop this class of medicine for most cancers.

“We are nonetheless making an attempt to grasp why some sufferers may profit greater than others,” stated Ting, who serves as director of the Tumor Cartography Center at Massachusetts General Hospital Cancer Center in Boston.

While acknowledging that extra analysis shall be wanted, Ting described the findings as “thrilling,” including that past colon most cancers it seems possible that “this [drug] technique could also be efficient throughout a number of most cancers sorts.”

Ting famous that HAART therapy for HIV sufferers — which is usually administered as a mix of a number of medicines — targets particular proteins known as “reverse transcriptases” (RT).

That’s as a result of HIV wants RTs to duplicate and unfold.

“[But] we and others have beforehand discovered that RT proteins in human cells are reactivated in most cancers,” defined Ting, additionally an affiliate professor of medication with Harvard Medical School. “Therefore, these RT medicine for HIV [also] have the flexibility to dam these human RTs present in most cancers.”

To underscore that time, Ting highlighted a 2018 analysis paper that discovered that sufferers dwelling with HIV whereas present process a three-drug “cocktail” of HAART remedy do, the truth is, are inclined to have a considerably decrease incidence of many sorts of most cancers than the overall inhabitants. That decrease danger, researchers discovered, consists of breast, prostateand colon most cancers.

For the brand new examine, Ting and his colleagues explored the potential of only one broadly used HAART treatment: lamivudine.

The trial concerned 32 sufferers, all of whom have been identified with superior colon most cancers that had unfold broadly, regardless of a collection of ordinary however unsuccessful most cancers remedies.

Ultimately, all of the sufferers got lamivudine, however at notably increased doses — approaching 400% extra — than is usually given to HIV sufferers. (HAART medicines are recognized to be “well-tolerated” amongst HIV sufferers, stated Ting, although he cautioned that it stays to be seen whether or not increased doses may give rise to new unwanted effects.)

Lamivudine was administered with out some other type of most cancers remedy. The consequence, Ting famous, was that eight of the sufferers noticed the development of their most cancers come to a halt, whereas yet another achieved a “combined response.”

None of the sufferers noticed their tumors shrink. But the group did observe encouraging “organic adjustments within the tumors after we checked out biopsies earlier than and after therapy,” Ting stated.

The findings have been revealed not too long ago within the journal Cancer Discovery.

The progression-halting impression that the HAART med appeared to have on colon most cancers means that “tumors behave in virus-like methods,” stated examine co-author Benjamin Greenbaum, an affiliate attending within the computational oncology service at Memorial Sloan Kettering Cancer Center in New York City.

In reality, Greenbaum stated, lamivudine’s impression on tumor cells is so much like its impression on HIV that it quantities to a “shocking” type of “viral mimicry.”

Still, the vast majority of sufferers didn’t seem to reap any profit. Ting prompt that in idea it is likely to be due to differing quantities of RT proteins discovered within the most cancers cells of particular person sufferers.

“We are…making an attempt to raised perceive which cancers are extra depending on this RT exercise, in order that we are able to have extra precision within the sufferers which may profit from this remedy,” he stated, stressing that the prospects for one of these most cancers intervention “are nonetheless within the early days.”

Even so, Dr. Andrew Chan — a professor within the division of medication at Harvard Medical School and vice chair of gastroenterology at Massachusetts General Hospital — stated that the potential for utilizing HAART meds to deal with superior most cancers would “characterize a brand new goal for therapy, which is admittedly thrilling, particularly if we are able to repurpose present medicine for different situations for which we’ve a wealth of scientific expertise.”

More info

There’s extra on the connection between HIV and most cancers danger on the U.S. National Cancer Institute.

SOURCES: David Ting, MD, affiliate scientific director, innovation and director, Tumor Cartography Center, Massachusetts General Hospital Cancer Center, and affiliate professor, drugs, Harvard Medical School, Boston; Benjamin Greenbaum, PhD, affiliate attending, computational oncology service, Memorial Sloan Kettering Cancer Center, New York City; Andrew Chan, MD, MPH, professor, division of medication, Harvard Medical School and vice chair, gastroenterology, Massachusetts General Hospital; Cancer Discovery, March 23, 2022

The post Could HIV Meds Help Slow Advanced Cancers? appeared first on Healthy and Slim Life.

WEDNESDAY, March 16, 2022 (HealthDay News) — Ever since routine prostate-specific antigen (PSA) screening exams have not been beneficial, there was a troubling rise in superior prostate most cancers instances within the United States, new analysis has discovered.

The exams measure the quantity of PSA within the blood, and elevated ranges can sign the presence of prostate most cancers.

Routine PSA screening started within the United States practically three a long time in the past, resulting in a drop in each superior prostate most cancers instances and prostate most cancers deaths. However, routine PSA screenings additionally elevated the danger of overdiagnosis and overtreatment of low-risk prostate most cancers.

This prompted the United States Preventive Services Task Force to suggest in 2008 towards routine PSA screening for males over 75, and comply with that with a 2012 advice towards such screening for all males. That advice was amended once more in 2018, to say that males aged 55-69 ought to focus on PSA screening with their medical doctors in the event that they desired.

To assess the influence of decreased screening, University of Southern California researchers analyzed knowledge on greater than 836,000 U.S. males 45 and older who have been identified with invasive prostate most cancers from 2004 to 2018.

Of these instances, superior most cancers was reported in additional than 26,600 males ages 45 to 74 and in additional than 20,500 males 75 and older.

Among males ages 45 to 74, the incidence price of superior prostate most cancers remained secure from 2004 to 2010, however then elevated 41% from 2010 to 2018.

For males 75 and older, the incidence price decreased from 2004 to 2011, however then elevated 43% from 2011 to 2018. In each age teams, the will increase have been throughout all races.

The findings have been revealed March 14 within the journal JAMA Network Open.

“This research is the primary to doc a continued rise in metastatic [advanced] prostate most cancers utilizing essentially the most up-to-date inhabitants dataset,” stated co-lead research creator Dr. Mihir Desai, a professor of medical urology at USC’s Keck School of Medicine.

“The discovery has essential ramifications for males as a result of prostate most cancers, when caught early, usually via a screening, may be very treatable and sometimes curable,” Desai added in a college information launch.

“This knowledge is essential because it signifies the necessity to continuously reassess the influence of coverage selections,” co-lead research creator Dr. Giovanni Cacciamani, an assistant professor of analysis urology and radiology at Keck. “Otherwise, we may even see a continued rise in metastatic prostate most cancers.”

The causes for halting routine PSA screenings might now be outdated, the researchers famous.

Co-author Dr. Inderbir Gill, chair of the urology division and government director of the USC Institute of Urology, identified that urologic facilities are discovering new methods to enhance affected person outcomes.

“More refined methods, together with biomarkers and magnetic resonance imaging [MRIs], have already elevated detection of clinically important cancers, whereas energetic surveillance is more and more used for low-risk and favorable intermediate-risk illness, thus mitigating the dangers of overtreatment,” Gill stated within the launch.

More info

There’s extra on prostate most cancers screening on the U.S. National Cancer Institute.

SOURCE: University of Southern California, information launch, March 14, 2022

The post With Fewer PSA Tests, Rate of Advanced Prostate Cancers Rose appeared first on Healthy and Slim Life.

WEDNESDAY, Feb. 9, 2022 (HealthDay News) — An experimental remedy that harnesses the physique’s tumor-fighting immune cells could also be efficient for some girls with superior breast most cancers, early analysis suggests.

The findings come from an ongoing trial on the U.S. National Cancer Institute (NCI). It is testing a brand new method to treating girls whose breast most cancers has unfold all through the physique and isn’t responding to straightforward therapies.

Researchers name it a “extremely customized” type of immunotherapy that makes use of sufferers’ personal immune system T cells to focus on their genetically distinctive most cancers.

At this level, the group is reporting on solely six girls who’ve undergone the immunotherapy. Three responded and have been cancer-free for at the very least 3.5 years, based on findings printed on-line Feb. 1 within the Journal of Clinical Oncology.

“This is very experimental and isn’t but authorized by the Food and Drug Administration,” pressured senior researcher Dr. Steven Rosenberg, chief of the surgical procedure department on the NCI’s Center for Cancer Research.

But, he mentioned, the preliminary findings provide “hope.”

Rosenberg mentioned the outcomes additionally go in opposition to the standard “dogma” that breast most cancers sometimes doesn’t illicit a lot of an immune response — and, subsequently, is often not prone to immunotherapy.

Immunotherapy refers to any remedy that enlists immune system defenses to battle a illness. There are numerous types of most cancers immunotherapy already authorized, however not all sorts of most cancers reply effectively to these medication.

Melanoma is a major instance of a most cancers that responds effectively, Rosenberg mentioned. Melanoma tumors carry many mutations, which may draw a robust immune response. And immunotherapy (notably medication referred to as checkpoint inhibitors) has remodeled the remedy of superior melanoma.

In distinction, breast tumors include comparatively few mutations, and there was restricted success up to now in treating superior breast most cancers with accessible immunotherapies. Checkpoint inhibitors are authorized for sure girls with an aggressive subtype of breast most cancers referred to as triple-negative.

The method Rosenberg’s group is creating is completely different. “We’re utilizing the affected person’s T cells because the drug,” he mentioned.

The researchers have up to now used the method to deal with sufferers with superior melanoma and sure different cancers, together with a uncommon gastrointestinal most cancers.

Specifically, the remedy depends on tumor-infiltrating lymphocytes — T cells present in and round a tumor. The concept is that, if these T cells are certainly reactive in opposition to the tumor, that may be enhanced and used as a weapon.

The present examine concerned 42 girls with metastatic breast most cancers that was not responding to standard therapies. Metastatic means their most cancers had unfold. Each affected person underwent surgical procedure to take away a tumor pattern, which the researchers genetically sequenced to determine its mutations.

They then remoted T cells from the tumor and, within the lab, examined the cells’ reactivity to the tumor’s particular mutations.

It turned out that in most sufferers — 67% — these T cells had been reactive to at the very least one among their tumor mutations.

Why weren’t these T cells killing the tumor?

The drawback, as Rosenberg defined it, is that tumors have methods for evading the immune response. So these tumor-infiltrating T cells weren’t sufficient on their very own.

The immunotherapy tactic seeks to assist. The affected person’s reactive T cells are multiplied within the lab to type a military, then infused again into the physique to hunt and destroy tumor cells.

Of the ladies on this trial, six had been in a position to bear the remedy, which additionally concerned 4 doses of the checkpoint inhibitor Keytruda (pembrolizumab). That was given earlier than the infusion, to maintain the newly launched T cells from being inactivated.

Of these six sufferers, three noticed their tumors shrink. One girl had a whole response, and stays cancer-free after greater than 5.5 years. The different two sufferers had a partial response, then underwent surgical procedure when some new tumor progress was discovered.

Both are actually cancer-free 5 and three.5 years, respectively, after receiving the immunotherapy.

“What we’re doing is creating a singular drug for every affected person,” Rosenberg mentioned. “That’s a brand new idea.”

Dr. Erica Mayer is an knowledgeable with the American Society of Clinical Oncology and an institute doctor on the Dana-Farber Cancer Institute in Boston.

“These are very constructive alerts,” she mentioned of the three sufferers’ outcomes.

Still, Mayer cautioned, way more stays to be discovered concerning the immunotherapy’s effectiveness and long-term security. Beyond that, she mentioned, there will likely be questions on the way to transfer such a fancy remedy into the actual world.

“Is this one thing that might be performed outdoors of specialised facilities?” Mayer mentioned.

She additionally famous that numerous immunotherapy approaches are being studied for breast most cancers, together with combining immunotherapy medication with different therapies, equivalent to “focused” medicines.

“Our progress ahead is dependent upon ongoing scientific trials, and sufferers’ participation in them,” Mayer mentioned.

More info

The U.S. National Cancer Institute has extra on breast most cancers remedy.

SOURCES: Steven Rosenberg, MD, chief, surgical procedure department, Center for Cancer Research, U.S. National Cancer Institute, Bethesda, Md.; Erica Mayer, MD, MPH, institute doctor, Dana-Farber Cancer Institute, Boston, and volunteer knowledgeable, American Society of Clinical Oncology, Alexandria, Va.; Journal of Clinical Oncology, Feb. 1, 2022, on-line

The post Immune-Based Therapy Shows Promise Against Advanced Breast Cancers appeared first on Healthy and Slim Life.

TUESDAY, Oct. 26, 2021 (HealthDay News) — High-dose radiation remedy could stall tumor development in sufferers with superior lung most cancers who aren’t absolutely responding to drug therapies, a preliminary examine suggests.

The examine concerned sufferers whose lung most cancers was thought of “oligoprogressive.” That means the most cancers had unfold to different websites within the physique, and the sufferers have been having a combined response to straightforward systemic therapies — together with focused medicine, immune system therapies and chemotherapy.

Essentially, the therapies have been efficiently suppressing development in a few of these distant tumors, however not others.

In the trial, the researchers discovered that making use of high-dose radiation to these drug-resistant websites prolonged sufferers’ progression-free survival — the period of time they remained secure.

Overall, sufferers who obtained radiation confirmed no most cancers development for a median of 44 weeks (which suggests half remained progression-free longer, and half for a shorter interval).

That was practically 5 instances longer than the median for sufferers given customary care, at 9 weeks.

The findings counsel the radiation approach could give these sufferers “extra mileage” out of their systemic drug therapies, mentioned lead researcher Dr. C. Jillian Tsai, a radiation oncologist at Memorial Sloan Kettering Cancer Center in New York City.

Doctors have been often utilizing the method in observe, on a case-by-case foundation, in accordance with Tsai. Sometimes a affected person is doing effectively on systemic remedy however just some lesions are not responding to the therapy, so medical doctors could strive focused radiation remedy to manage these growths.

Until not too long ago, although, the tactic had not been examined in scientific trials. Three such research at the moment are ongoing, Tsai mentioned.

More proof is required earlier than the method can change into the usual of care, mentioned Dr. Steven Chmura, a radiation oncologist on the University of Chicago who was not concerned within the analysis.

“This is the primary examine to check this method formally, asking if we are able to lengthen the usage of a systemic agent when it is working effectively in many of the physique and solely failing in a couple of spots,” Chmura mentioned.

“A part 3 trial is required to actually change the usual of care and scientific pointers,” he mentioned, referring to the ultimate part in scientific testing of a brand new remedy.

Tsai offered the findings Sunday on the annual assembly of the American Society for Radiation Oncology in Chicago. Studies offered at conferences are typically thought of preliminary till they’re printed in a peer-reviewed journal.

The trial concerned 58 sufferers with metastatic lung most cancers and 44 with metastatic breast most cancers. Metastatic means the preliminary most cancers had unfold to different websites within the physique. All sufferers had one to 5 lesions that have been progressing regardless of systemic remedy.

Tsai’s workforce randomly assigned the sufferers to have both stereotactic physique radiation remedy (SBRT) or customary care. SBRT is a broadly used approach designed to ship exact, excessive doses of radiation to the most cancers web site and spare surrounding tissue, Tsai defined.

While lung most cancers sufferers who obtained SBRT remained progression-free for a median of 44 weeks, in comparison with 9 weeks for many who didn’t bear radiation, no such profit was seen in breast most cancers sufferers.

“It could also be due to the totally different biology of the illnesses,” Tsai mentioned. She famous that in breast most cancers sufferers, the lesions handled with radiation did reply — however new ones developed.

More analysis is required to completely perceive the totally different outcomes for breast most cancers sufferers, Tsai mentioned. She mentioned her workforce additionally desires to determine which traits make particular person sufferers extra possible to answer the radiation remedy.

As for potential unwanted effects of SBRT, they range relying on the place the radiation is given. If it is delivered to the bones, for instance, it may well trigger a short lived ache flare-up, Tsai mentioned. If the radiation is to the lungs, it may well trigger irritation.

During the trial, eight sufferers given radiation had at the least a reasonably extreme aspect impact.

While part 3 trials haven’t been performed but, it’s potential for lung most cancers sufferers like these on this examine to get radiation remedy.

Chmura mentioned, “I believe if a affected person with [lung cancer] is doing effectively on systemic remedy however is advised they’re progressing in a couple of small spots, it will be helpful for them to know this therapy choice exists.”

SBRT has been used for a couple of decade, he famous, and is broadly obtainable world wide.

More info

The American Cancer Society has extra on lung most cancers therapy.

SOURCES: C. Jillian Tsai, MD, PhD, radiation oncologist, and director, metastatic illness radiation oncology analysis, Memorial Sloan Kettering Cancer Center, New York City; Steven Chmura MD, PhD, director, scientific and translational analysis for radiation oncology, University of Chicago; presentation, American Society for Radiation Oncology annual assembly, Chicago, Oct. 24, 2021

The post Targeted High-Dose Radiation Helps Fight Advanced Lung Cancer appeared first on Healthy and Slim Life.